BioPharmSignal logoBioPharmSignal

Biotech News

Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution

Kiniksa (KNSA)Kiniksa2026-06-25 13:46 ESTEarnings

– ARCALYST ® (rilonacept) Q3 2025 net product revenue of $180.9 million, representing 61% year-over-year growth – – ARCALYST 2025 expected net product revenue raised to $670 - $675 million – – KPL-387 granted Orphan Drug Designation for the treatment of pericarditis – – Cash balance increased by

Open original release

Related news

KNSAKiniksa2026-06-25 13:46 EST

Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences

KNSAKiniksa2026-06-25 13:46 EST

Kiniksa Pharmaceuticals to Present at Jefferies Global Healthcare Conference in London

KNSAKiniksa2026-06-25 13:46 EST

Kiniksa Pharmaceuticals to Present at 44th Annual J.P. Morgan Healthcare Conference

KNSAKiniksa2026-06-25 13:46 EST

Kiniksa Pharmaceuticals Provides Corporate Update

KNSAKiniksa2026-06-25 13:46 EST

Kiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

KNSAKiniksa2026-06-25 13:46 EST

Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Portfolio Execution

KNSAKiniksa2026-06-25 13:46 EST

Kiniksa Pharmaceuticals to Present at TD Cowen 46th Annual Health Care Conference

KNSAKiniksa2026-06-25 13:46 EST

Kiniksa Pharmaceuticals Launches Targeted Direct-To-Consumer TV Campaign for ARCALYST® (rilonacept) in Recurrent Pericarditis

KNSAKiniksa2026-06-25 13:46 EST

Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution

KNSAKiniksa2026-06-25 13:46 EST

Kiniksa Pharmaceuticals to Report First Quarter 2026 Financial Results on April 28, 2026

View all latest news

Kiniksa

Kiniksa is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

KNSAKiniksa2026-06-26 08:50 EST

Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences

KNSAKiniksa2026-06-26 08:50 EST

Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution

KNSAKiniksa2026-06-26 08:50 EST

Kiniksa Pharmaceuticals to Present at Jefferies Global Healthcare Conference in London

KNSAKiniksa2026-06-26 08:50 EST

Kiniksa Pharmaceuticals to Present at 44th Annual J.P. Morgan Healthcare Conference

KNSAKiniksa2026-06-26 08:50 EST

Kiniksa Pharmaceuticals Provides Corporate Update

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biotechnology
Location
United States